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The pleural mesothelium, derived from the embryonic mesoderm, is formed by a
metabolically active monolayer of cells that blanket the chest wall and lungs on the parietal
and visceral surfaces, respectively. The pleura and lungs are formed as a result of an
intricate relationship between the mesoderm and the endoderm during development.
Mesenchymal signaling pathways such as Wnt/B-catenin, Bmp4, and sonic hedgehog
appear to be quintessential for lung development. Pleural Mesothelial Cells (PMCs)
are known to express Wilms tumor-1 (Wt1) gene and in lineage labeling studies of
the developing embryo, PMCs were found to track into the lung parenchyma and
undergo mesothelial-mesenchymal transition (MMT) to form α-smooth muscle actin
(α-SMA)-positive cells of the mesenchyme and vasculature. There is definite evidence
that mesothelial cells can differentiate and this seems to play an important role in
pleural and parenchymal pathologies. Mesothelial cells can differentiate into adipocytes,
chondrocytes, and osteoblasts; and have been shown to clonally generate fibroblasts
and smooth muscle cells in murine models. This supports the possibility that they
may also modulate lung injury-repair by re-activation of developmental programs in
the adult reflecting an altered recapitulation of development, with implications for
regenerative biology of the lung. In a mouse model of lung fibrosis using lineage-tracing
studies, PMCs lost their polarity and cell-cell junctional complexes, migrated into lung
parenchyma, and underwent phenotypic transition into myofibroblasts in response to
the pro-fibrotic mediator, transforming growth factor-β1 (TGF-β1). However, intra-pleural
heme-oxygenase-1 (HO-1) induction inhibited PMC migration after intra-tracheal fibrogenic
injury. Intra-pleural fluorescein isothiocyanate labeled nanoparticles decorated with a
surface antibody to mesothelin, a surface marker of mesothelial cells, migrate into the
lung parenchyma with PMCs supporting a potential role for pleural based therapies to
modulate pleural mesothelial activation and parenchymal disease progression.
Keywords: pleural mesothelium, pleural mesothelial cells, idiopathic pulmonary fibrosis (IPF), Wilms tumor-1
(WT1), epithelial-mesenchymal transition (EMT)
INTRODUCTION
The lung is a complex, integrated structure of airways, vasculature
and interstitium, surrounded by the pleural mesothelium (Jantz
and Antony, 2006). The pleural mesothelium, derived from the
embryonicmesoderm, is formed by a layer of cells that blanket the
chest wall and lungs on the parietal and visceral surfaces, respec-
tively. A complex interplay of signaling pathways such as Wnt/β-
catenin, Bone morphogenetic protein 4 (Bmp4), sonic hedgehog,
and Fibroblast growth factor 10 (Fgf10) between the developing
endoderm and mesoderm is essential for development.
Wilms tumor-1 (Wt1), a zinc finger transcription factor
(Haber et al., 1990), is expressed in certain mesoderm-derived
Abbreviations: PMCs, Pleural Mesothelial Cells (PMCs); Wt1, Wilms tumor-1
(Wt1); MMT, Mesothelial-mesenchymal transition (MMT); α-SMA, α-smooth
muscle actin; Bmp4, Bone morphogenetic protein 4; Shh, Sonic hedgehog;
Fgf10, Fibroblast growth factor 10; IPF, Idiopathic Pulmonary Fibrosis; TGF-
β1, Transforming growth factor-β1; HO-1, Heme-oxygenase-1 (HO-1); EMT,
Epithelial-mesenchymal transition; NOX-4, NADPH oxidase-4; UIP, Usual inter-
stitial pneumonia; RNA, Ribonucleic acid; BAL, Bronchoalveolar lavage; NP,
Nanoparticle; FITC, Fluorescein isothiocyanate; PLGA, Poly-lactic-co-glycolic acid.
tissues including the pleura (Park et al., 1993) and is known to
regulate many functional properties of the developing mesothe-
lium (Ito et al., 2006; Jomgeow et al., 2006). It also regulates
pleural mesothelial cell (PMC) plasticity. Wt1 expressing PMCs
have been shown to migrate into the lung parenchyma and dif-
ferentiate into subpopulations of bronchial smooth muscle cells,
vascular smooth muscle cells and fibroblasts (Colvin et al., 2001;
Dixit et al., 2013).
The presence of Wt1-expressing PMCs on both the pleural
surface and in the lung parenchyma of patients with IPF sug-
gests a role for crosstalk between the parenchymal lung injury
and activation of the pleural mesothelium in the pathogen-
esis of IPF. PMCs migrate into the pulmonary parenchyma
in IPF and transition into myofibroblasts suggesting the novel
hypothesis that IPF is an altered, recapitulation of devel-
opment, with implications for regenerative biology of the
lung.
PMCs could represent a new cellular therapeutic target
in a disease where we currently lack treatment modalities.
Intra-pleural delivery of compounds is a lung targeted, innovative
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therapeutic modality that can be refined to deliver drugs,
minimizing systemic toxicity.
DEVELOPMENT
The lungs arise from the anterior foregut endoderm via a com-
plex and highly regulated process comprising of the embryonic
stage, pseudo-glandular stage, branchingmorphogenesis, canalic-
ular stage, saccular stage, and the alveolarization stage. During all
stages of endodermal development, the lung mesoderm interacts
with the lung endoderm to generate the various lineages within
the lung (Herriges and Morrisey, 2014) and plays a central role in
regulating morphogenesis of the lung, including branching, lung
size, and vascular development (Que et al., 2008).
ROLE OF MESODERM DURING DEVELOPMENT
The lung mesoderm is an important source of paracrine sig-
nals such as Fgf10 and Wnt2 (Bellusci et al., 1997; Sekine
et al., 1999; Weaver et al., 2000; Goss et al., 2009), which
are essential for multiple processes during lung develop-
ment, including the patterning of early endoderm progeni-
tors, epithelial proliferation, and differentiation. The mature
lung contains many mesodermal derivatives, including air-
way smooth muscle, vascular smooth muscle, endothelial and
mesothelial cells, as well as multiple less well-understood cell
types, such as pericytes, alveolar fibroblasts, and lipofibrob-
lasts (Herriges and Morrisey, 2014). In lineage labeling stud-
ies of the developing embryo, PMCs were found to track into
the lung parenchyma and undergo mesothelial-mesenchymal
transition (MMT) to form α-smooth muscle actin (α-SMA)-
positive cells of the mesenchyme and vasculature (Que et al.,
2008).
SIGNALING PATHWAYS
During development, Wnt/β-catenin signaling is responsible for
specifying Nkx2.1+ respiratory endoderm progenitors, which
mark the specification of the respiratory system in the ante-
rior foregut endoderm (Herriges and Morrisey, 2014). This, in
turn, is dependent upon active Bmp signaling that represses
the transcription factor Sox2, thereby allowing for expres-
sion of Nkx2.1. Loss of Bmp signaling through inactivation
of the Bmp receptors, Bmpr1a and Bmpr1b, leads to tra-
cheal agenesis with retention of the branching region of the
lungs (Domyan et al., 2011). Moreover, signaling between the
developing endoderm and mesoderm appears to be essential
for branching morphogenesis and the loss of Fgf10 signal-
ing to Fgfr2 in the developing endoderm leads to disrup-
tion of branching (Sekine et al., 1999; Ohuchi et al., 2000).
Fgf10 expression is regulated by several signaling pathways
such as Bmp4 and sonic hedgehog (Shh), suggesting a com-
plex interplay of signaling molecules during development
(Bellusci et al., 1997; Pepicelli et al., 1998; Weaver et al.,
2000).
Wt1
The Wt1 gene encodes a 49–52 kDa protein with an N-terminal
domain that is involved in protein-RNA interactions critical for
its transcriptional regulatory function (Call et al., 1990).
Wt1 IN PRENATAL DEVELOPMENT
PMCs are known to express Wt1 gene and migrate into the lung
parenchyma to form smooth muscle cells of the vascular wall, as
well as other cells of the lung mesenchyme during development
(Que et al., 2008; Zhou et al., 2010, 2011).
Recent cell lineage labeling studies in the developing heart
provide evidence that the surface epicardial mesothelium under-
goes epithelial-mesenchymal transition (EMT) and migrates into
the myocardium where it differentiates into various cell types,
including endothelium, smooth muscle cells, and cardiomyocytes
(Mikawa and Gourdie, 1996; Dettman et al., 1998; Cai et al.,
2008; Zhou et al., 2010). In addition, lineage tracing and other
studies show that the serosal mesothelium of the gut also con-
tributes the majority of vascular smooth muscle cells (Wilm et al.,
2005; Kawaguchi et al., 2007). A major role of Wt1 and PMCs
in mesenchymal differentiation and development was demon-
strated by lineage tracing studies in the embryonic mouse (Colvin
et al., 2001). PMCs were shown to readily migrate into the lung
parenchyma and express α-SMA. Another recent study employing
Wt1CreERT2/+ mice visualized Wt1+ mesothelial cell entry into
the lung by live imaging, identified their progenies in subpopula-
tions of bronchial smooth muscle cells, vascular smooth muscle
cells, and desmin+ fibroblasts by lineage tagging; and demon-
strated that mesothelial cell movement into the lung requires
the direct action of sonic hedgehog (shh) signaling (Dixit et al.,
2013). Together, these studies demonstrate that the mesothelium
lining of serosal surfaces of multiple organ systems plays a criti-
cal role during development and organogenesis, supporting the
possibility that they may also modulate lung injury-repair by
re-activation of developmental programs in the adult.
Wt1 IN POSTNATAL DISEASE
Wt1 can induce a morphological transition from an epithelial
phenotype to a mesenchymal phenotype (Burwell et al., 2007).
It is a potent transcription factor that can function as a tumor
suppressor (Zhang et al., 2003), or as an oncogene depending
on the cell type (Loeb et al., 2001; Oji et al., 2002; Ueda et al.,
2003). It was in fact initially discovered as a tumor suppres-
sor gene in Wilms tumor of the kidney (Haber et al., 1990).
Wt1 demonstrates tissue specific responses and is recognized to
regulate TGF-β1 in the kidney. In other cell types such as hemato-
logical cells it is reported to confer oncogenic properties (Licciulli
and Kissil, 2010). Wt1 is expressed in normal pleural mesothe-
lium, and is over-expressed in malignant mesothelioma (Amin
et al., 1995). However, there is limited information of the role of
Wt1 in non-malignant lung diseases.
Wt1 IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
Several studies support a role for Wt1 in mesothelial-to-
mesenchymal transition (MMT) (Burwell et al., 2007; Bax et al.,
2011a,b). Hecker et al. have evaluated the responses of PMCs to
TGF-β1, their expression of MMT markers such as e-cadherin,
α-SMA, vimentin; their contractile ability using a collagen gel
contraction assay (Hecker et al., 2009); and also biological
functional assays such as migration and proliferation (Hecker
et al., 2009). Studies indicate a role for TGF-β1 in mediating
MMT (Nasreen et al., 2009). For example, treatment of mouse
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PMCs with TGF-β1 increased expression of the myofibroblast
markers α-SMA and NADPH oxidase-4 (NOX-4) (Zolak et al.,
2013). Wt1-expressing PMCs are present both on the pleu-
ral surface and in the lung parenchyma of patients with IPF
suggesting their role in the pathogenesis of IPF. However, the
precise relationship between Wt1 and TGF-β1 remains unclear.
Also, the role of Wt1 in regulating PMC plasticity needs to be
analyzed.
PLURIPOTENCY OF MESOTHELIAL CELLS
Although mesenchymal in origin, mesothelial cells exhibit char-
acteristics such as a polygonal cell shape, expression of surface
microvilli, epithelial cytokeratins, and tight junctions, which are
typical of epithelial cells (Mutsaers, 2002). During development,
endothelium and vascular smooth muscle cells of the vascular
system, heart, liver and gut are derived from the differentia-
tion of mesothelium via a process of epithelial-to-mesenchymal
transition (EMT) (Munoz-Chapuli et al., 1999; Perez-Pomares
et al., 2002, 2004). Increasing evidence suggests existence of a
population of progenitor-like mesothelial cells with the capacity
to differentiate into cells of different phenotypes (Herrick and
Mutsaers, 2004). By targeting mesothelin and using a genetic
eage to trunk fibroblasts, smooth muscle cells, and vasculature
(Rinkevich et al., 2012).
Recently, primary rat and human mesothelial cells, when
maintained in osteogenic or adipogenic media, were shown
to differentiate into osteoblast- and adipocyte-like cells via
epithelial-to-mesenchymal transition as suggested by the changes
in mRNA expression of these cells. This supports mesothelial
cell differentiation as the potential source of different tissue
types in malignant mesothelioma and other serosal pathologies
(Lansley et al., 2011). The term mesodermoma was introduced
by Donna and Betta to define neoplasms arising from undif-
ferentiated and multipotential mesoderm (Donna and Betta,
1981).
Mesothelial cells appear to retain the ability to produce mes-
enchyme, including smooth muscle cells, in response to trans-
forming growth factor-β1 (TGF-β1) and platelet derived growth
factor (Wada et al., 2003; Kawaguchi et al., 2007). Moreover,
mesothelial cells have been shown to adopt a myofibroblast
phenotype in vitro, in response to TGF-β1 (Yang et al., 2003).
Transfection of the peritoneum and pleura of rats with an ade-
novirus expressing TGF-β1induced mesothelial cells to undergo
EMT with subsequent fibrotic changes (Margetts et al., 2005;
Decologne et al., 2007).
The significance of EMT in malignant pleural mesothelioma
(MPM) was demonstrated by Schramm et al. in their study of
a retrospective cohort of 352 patients. Immunohistochemistry
of a tissue microarray showed that the activation of periostin-
triggered EMT is associated with the sarcomatoid histotype of
malignant mesothelioma and has an impact on shorter survival of
patients (Schramm et al., 2010). Periostin secretion by MPM cells
has in turn been shown to be upregulated by CD26 (Komiya et al.,
2014), the expression of which is increased in various cancers
(Havre et al., 2008).
IDIOPATHIC PULMONARY FIBROSIS (IPF)
SUB-PLEURAL DISTRIBUTION
IPF is a progressive lung disease process that appears to begin
in the sub-pleural regions, and then extend centrally. This sub-
pleural and basilar distribution, which is the defining feature
of idiopathic pulmonary fibrosis (IPF) has not been adequately
explained (King et al., 2011). However, this pattern of distribution
suggests pleural involvement in the disease process.
MYOFIBROBLASTS AND FIBROBLASTIC FOCI
The presence of myofibroblasts in fibrobastic foci in lungs of
patients with IPF is well-established. The fibroblast and myofi-
broblast foci secrete excessive amounts of extracellular matrix,
mainly collagens, resulting in scarring and destruction of the lung
architecture. The profusion of fibroblastic foci is predictive of sur-
vival in IPF patients (King et al., 2001a,b). A recent study has
shown that the hallmark lesion in usual interstitial pneumonia
(UIP), fibroblastic foci, on three-dimensional histo-pathological
reconstruction are part of a complex and highly interconnected
reticulum of fibrous tissue that extends from the pleura into
the lung parenchyma (Cool et al., 2006). Neither the origin of
these myofibroblasts nor the molecular mechanisms involved in
the formation of fibroblastic foci have been well-defined (Phan,
2008).
While a number of cellular source(s) and progenitors of tis-
sue myofibroblasts have been proposed, none of these hypotheses
provide a indisputable explanation for the histo-pathological pat-
tern of usual interstitial pneumonia (UIP) and its peripheral
localization (Raghu et al., 2011). However, evidence suggests that
abnormal recapitulation of developmental pathways and epige-
netic changes may play a role in the pathogenesis of IPF (King
et al., 2011). IPF is a devastating disease with an inexorable course
and its pathogenesis remains unclear. There are no therapies
that directly impact the disease progression or mortality, and we
urgently need innovative new ideas that will impact therapeu-
tics in this disease (King et al., 2011; Raghu et al., 2011). PMCs
serve as myofibroblast progenitors in animal models of fibrosis,
and therapeutic targeting of these cells may be effective as an
anti-fibrotic approach (Que et al., 2008).
PLEURAL MESOTHELIAL CELLS IN IPF
PMCs are metabolically active cells (Antony, 2003; Mohammed
et al., 2007), responsive to their microenvironment (Antony,
2003), and are recognized to demonstrate plasticity of their phe-
notype (Nasreen et al., 2009).The presence of calretinin and
mesothelin (markers of mesothelial cells) (Mubarak et al., 2012)
and Wt-1 expressing PMCs (Zolak et al., 2013) was recently
demonstrated in parenchymal cells of explanted lung tissues from
16 patients with IPF supporting a role for PMC differentiation
and their trafficking into the lung as contributors to the myofi-
broblast population in lung fibrosis. It is not known if the number
or profusion of PMCs may be predictive of the severity and/or
progression of IPF.
The Ashcroft score is a score for histo-pathological grading of
pulmonary fibrosis (Hagiwara et al., 2000; Matsuoka et al., 2002;
Simler et al., 2002; Murakami et al., 2006). There exists a cor-
relation between the number of calretinin-positive cells and the
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degree of fibrotic change in the parenchyma, as measured by the
Ashcroft score. Whether the number of calretinin-positive cells
wasmeasured as a raw number, or as percentage of the total nucle-
ated cells seen in a photomicrograph, the correlation with the
degree of fibrosis was highly significant (Mubarak et al., 2012).
These studies suggest that PMCs may represent a novel cellular
biomarker of disease activity, and more importantly, play a role in
the tissue remodeling responses seen in patients with IPF.
Recent studies demonstrate that PMCs cells lose their polarity
and cell-cell junctional complexes, migrate into lung parenchyma,
and undergo phenotypic transition into myofibroblasts in
response to the pro-fibrotic mediator, TGF-β1 (Nasreen et al.,
2009; Mubarak et al., 2012). The transition of PMC tomyofibrob-
lasts is dependent on smad-2 signaling and knockdown of smad-2
gene by silencing small interfering RNA significantly suppresses
the transition of PMCs to myofibroblasts and inhibits PMC hap-
totaxis (Nasreen et al., 2009). We have demonstrated in a murine
model, that TGF-β1 induces PMC trafficking into the lung and
differentiation into myofibroblasts. Moreover, carbon monoxide
or the induction of heme oxygenase-1 (HO-1) inhibits the expres-
sion of myofibroblast markers, contractility, and haptotaxis in
PMCs treated with TGF-β1. These findings support a potential
role for pleural-based therapies to modulate pleural mesothe-
lial activation and parenchymal fibrosis progression (Zolak et al.,
2013).
PLEURAL MESOTHELIAL CELLS AS A POTENTIAL
THERAPEUTIC TARGET
PMCsmigrate into the pulmonary parenchyma in IPF and transi-
tion into myofibroblasts. This invokes a novel, alternative hypoth-
esis for the origin and source of the myofibroblasts in the lungs
of patients with IPF, and provides a rational explanation for the
spatio-temporal distribution of fibrosis in IPF. PMCs could rep-
resent a new cellular therapeutic target in a disease where we
currently lack treatment options. Intra-pleural delivery of com-
pounds is a lung targeted, innovative therapeutic modality that
can be refined to deliver drugs, minimizing systemic toxicity.
Direct delivery of the small molecule inhibitors to the pleura
could potentially have several advantages: (Jantz and Antony,
2006) It can potentially provide a direct, high concentration of the
compound to target the pro-fibrogenic activities of PMCs; (Haber
et al., 1990) Intra-pleural delivery might delay systemic absorp-
tion, protecting against systemic toxicity while increasing efficacy;
(Park et al., 1993) Intra-pleural delivery may result in higher, sus-
tained levels in the Bronchoalveolar lavage (BAL) when compared
with serum levels (Mubarak et al., 2012); and (Jomgeow et al.,
2006) innovative, less invasive methods of accessing the pleural
space such as tunneled pleural catheters could make intra-pleural
delivery a viable option in patients.
There are several methods that can be utilized for site-
directed delivery of therapeutic agents. These include liposo-
mal drug delivery, nanoparticle (NP) delivery of proteins, and
gene therapy (Watanabe et al., 2010). Several of these meth-
ods have been utilized to target the pleura (Perez-Soler et al.,
1997; Liu et al., 2006; Watanabe et al., 2010). We have demon-
strated that PMCs migrate into the parenchyma (Zolak et al.,
2013). Biodegradable fluorescein isothiocyanate (FITC) labeled
PLGA (poly-lactic-co-glycolic acid) nanoparticles (which can
carry therapeutic compounds conjugated to PLGA) decorated
with antibody targeted to mesothelin (a PMC marker) localize
to the pleural surface in control mice, but diffuse into the lung
parenchyma in mice given intra-tracheal bleomycin (Figure 1). It
appears that intra-pleural delivery of molecules to the lung is fea-
sible, albeit, with the recognition that refinement of techniques
for minimal lung injury will be required.
CONCLUSION
The pleural mesothelium is a derivative of the embryonic meso-
derm. Several complex pathways of interplay between the meso-
derm and endoderm lead to the development of the lungs and
pleura. Lineage labeling and other studies have shown the abil-
ity of the PMCs to undergo MMT to form other mesenchymal
structures and have therefore established their pluripotency dur-
ing development. Moreover, recent studies have shown that the
plasticity of mesothelial cells is retained postnatally and gives
them the ability to migrate and differentiate into other cell
types. This supports the possibility that PMCs may modulate
lung injury-repair by reactivation of developmental programs
in the adult, reflecting an altered recapitulation of development
with implications for regenerative biology of the lung. We have
shown that PMCs are present in the lung parenchyma in lungs
with IPF. Also, PMC migration into lung parenchyma and phe-
notypic transition into myofibroblasts can be induced by the
pro-fibrotic mediator, TGF-β1 and is inhibited by intra-pleural
heme-oxygenase-1 (HO-1). The possible role of PMCs in disease
pathogenesis and/or progression of IPF makes them an attractive
cellular target for potential therapeutic interventions in a dis-
ease where we currently lack treatment modalities. Intra-pleural
delivery of compounds is a lung targeted, innovative therapeutic
modality that can be refined to deliver drugs, thereby minimizing
systemic toxicity. Intra-pleural fluorescein isothiocyanate labeled
nanoparticles decorated with a surface antibody to mesothe-
lin, a surface marker of mesothelial cells, migrate into the lung
parenchyma with PMCs supporting a potential role for pleural
based therapies to modulate pleural mesothelial activation and
parenchymal disease progression. However, further studies are
FIGURE 1 | Intra-pleural delivery of PLGA NP. Biodegradable FITC labeled
PLGA nanoparticles (which can carry therapeutic compounds conjugated to
PLGA) decorated with antibody targeted to mesothelin (a PMC marker)
localize to the pleural surface in control mice treated with saline (A), but
diffuse into the lung parenchyma in mice given intra-tracheal bleomycin (B).
The arrow point to FITC labeled PLGA nanoparticles. PLGA, Poly
Lactic-co-Glycolic Acid; NP, Nanoparticles; FITC, Fluorescein isothiocyanate.
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needed to develop such therapies and effective pleural-based drug
delivery systems.
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